Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01760525 |
| Title | A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors |
| Acronym | CCGM097X2101 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | FRA | DEU | CHE |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Dana Farber Cancer Institute SC (2) | Boston | Massachusetts | 02215 | United States | Details | |
| Novartis Investigative Site | Lyon Cedex | 69373 | France | Details | ||
| Novartis Investigative Site | Essen | 45147 | Germany | Details | ||
| Novartis Investigative Site | Singapore | 169610 | Singapore | Details | ||
| Novartis Investigative Site | Zuerich | 8091 | Switzerland | Details |